IMD-1743

IMD-1743 is a tumor microenvironment-activated T-cell engager (TMEA-TCE) targeting Claudin 6 (CLDN6) and CD3, developed by Immune-Onc Therapeutics. It is designed to overcome the systemic toxicities, such as cytokine release syndrome (CRS), often associated with traditional T-cell engagers. The molecule features an anti-CD3 domain that is masked by a legumain-cleavable linker. Legumain is a protease that is highly overexpressed in the extracellular space of the tumor microenvironment (TME) across various solid tumors. Upon reaching the TME, legumain cleaves the linker, unmasking the CD3-binding domain and allowing the TCE to simultaneously bind CLDN6 on tumor cells and CD3 on T cells. This localized activation facilitates T-cell-mediated lysis of CLDN6-expressing cancer cells while minimizing systemic T-cell activation. Preclinical studies have demonstrated potent anti-tumor activity in ovarian and hepatocellular carcinoma models, with a favorable safety profile and high stability in circulation.

Other names

CLDN6-CD3 TMEA-TCECLDN-6-CD3 TMEA-TCECLDN 6-CD3 TMEA-TCECLDN6-CD3 tumor microenvironment-activated T-cell engagerCLDN-6-CD3 tumor microenvironment-activated T-cell engagerCLDN 6-CD3 tumor microenvironment-activated T-cell engager